Companies beating expectations at a clip well above normal
On a Thursday morning in May 2021, European equity markets drifted quietly toward historic highs — not on euphoria, but on the steady accumulation of evidence that the continent's economy was healing faster than expected. Corporate earnings were beating forecasts at nearly twice the historical rate, and economic data from Germany to Britain suggested that recovery was no longer a projection but a present reality. Yet embedded in every piece of good news was a quiet paradox: the stronger the recovery, the sooner the extraordinary monetary support that had sustained markets through the crisis would need to be withdrawn.
- The STOXX 600 hovered just below its all-time high, carried upward by an earnings season in which nearly three-quarters of reporting companies surpassed profit expectations — almost double the historical norm.
- AB Inbev surged over 5% on strong quarterly results and a CEO transition that markets read not as disruption but as confidence, while Italian and French banks climbed 4-5% on their own beats, pushing the eurozone banking sector to a 14-month high.
- A shadow fell on vaccine makers Novavax and Moderna, whose Frankfurt-listed shares dropped nearly 10% after President Biden backed waiving intellectual property protections on COVID-19 vaccines, threatening the pricing power that had made them pandemic-era darlings.
- Economic data sharpened the recovery picture — German industrial orders surged beyond forecasts and Britain's services sector grew at its fastest pace in seven years — but each strong reading brought central banks one step closer to the uncomfortable question of when to begin withdrawing stimulus.
- In London, the FTSE 100 edged higher as traders awaited the Bank of England's policy signal, with analysts warning that any hawkish turn could push the index back below 7,000, even as retailers Next and Superdry posted results that spoke to genuine consumer resilience.
Thursday morning in European markets carried the texture of quiet momentum — the kind that suggests something larger is building beneath the surface. The STOXX 600 edged up 0.1% to 422 points, close enough to its all-time high of 433.61 that the distance felt almost symbolic. The backdrop was unmistakably constructive: companies were beating profit expectations at nearly twice the historical rate, and a week's worth of economic data had painted a picture of recovery that was not merely hoped for but measurably underway.
Anheuser-Busch InBev led the session, jumping 5.2% after first-quarter earnings exceeded analyst forecasts. The company also announced that Michel Doukeris would succeed Carlos Brito as chief executive — a leadership change that investors chose to read as confidence rather than uncertainty. Volkswagen edged higher after raising its operating margin target for the year. The banking sector added another pillar of support: UniCredit climbed 4.7% and Societe Generale rose 4.0%, both on stronger-than-expected quarterly results, lifting the eurozone banking index to a fresh 14-month high.
Not every story was one of gains. Frankfurt-listed shares of Novavax and Moderna each fell close to 10% after President Biden announced support for waiving intellectual property protections on COVID-19 vaccines — a move that cast doubt over the pricing power that had defined their pandemic-era valuations.
In London, the FTSE 100 rose 0.2% as traders positioned ahead of the Bank of England's monetary policy decision. The central bank was expected to signal a stronger-than-forecast recovery — and possibly hint at the eventual unwinding of its emergency support measures. Retailers offered their own evidence of consumer resilience: Next raised its full-year profit guidance, gaining 3.0%, while Superdry rallied 12.0% on a return to growth driven by online and wholesale channels.
The week's economic data reinforced the broader narrative. German industrial orders jumped more than expected in March, and Britain's services sector recorded its fastest expansion in over seven years. These were real signals — of hiring, investment, and spending returning. But they carried an implicit tension that every market participant understood: the stronger the recovery, the sooner central banks would face the question of when to withdraw the monetary support that had kept equities aloft. That reckoning had not yet arrived — but it was no longer distant.
Thursday morning in European markets brought the kind of quiet momentum that suggests something larger is building. The STOXX 600, the continent's broadest stock index, edged up 0.1% to settle at 422 points—close enough to its all-time high of 433.61 that traders could almost taste it. The move was modest, but the backdrop was unmistakably bullish: companies were beating profit expectations at a clip well above normal, and the economic data flowing in all week painted a picture of genuine recovery taking hold.
Anheuser-Busch InBev led the charge, jumping 5.2% after delivering first-quarter earnings that exceeded what analysts had penciled in. The brewer also announced a leadership change—Michel Doukeris, who runs the North America business, will take over as chief executive from Carlos Brito. It was the kind of news that typically unsettles markets, but investors read it as a sign of confidence in the company's direction. Food and beverage stocks broadly benefited, as did utilities and chemicals. Volkswagen, Europe's largest automaker, crept higher on news that it was raising its operating margin target for the year.
The banking sector provided another pillar of support. UniCredit, Italy's second-largest bank, climbed 4.7%, while the French lender Societe Generale rose 4.0%—both had reported quarterly earnings that came in above expectations. The broader eurozone banking sector gained 0.4% and hit a fresh 14-month high. These were not explosive moves, but they reflected a deepening confidence that European financial institutions had weathered the pandemic and were now positioned to benefit from the economic reopening.
The earnings picture across the continent was striking. Of the STOXX 600 companies that had reported so far, 73% had beaten profit expectations, according to Refinitiv IBES data. Normally, only 51% clear that bar. It suggested that either companies had been conservative in their guidance or that the recovery was genuinely outpacing what most had anticipated. There were exceptions: Frankfurt-listed shares of U.S. drugmakers Novavax and Moderna both fell close to 10% after President Joe Biden announced support for waiving intellectual property protections on COVID-19 vaccines, a move that threatened their pricing power.
In London, the FTSE 100 rose 0.2% as traders braced for the Bank of England's monetary policy decision. The central bank was widely expected to signal that Britain's economic recovery would be stronger than previously forecast—and potentially to hint that it might begin winding down the emergency support measures it had deployed during the crisis. Connor Campbell, a market analyst at SpreadEX, noted the tension: as the UK economy strengthened, the central bank would face pressure to taper stimulus, and any hawkish signals could send the FTSE back below 7,000. British retailers showed their own strength—Next gained 3.0% after raising full-year profit guidance, while Superdry rallied 12.0% on a return to growth in its fourth quarter, buoyed by online and wholesale channels.
The week had delivered a steady stream of economic data that reinforced the recovery narrative. German industrial orders jumped more than expected in March, driven by strong domestic demand for consumer goods. Britain's services sector recorded its fastest growth in more than seven years. These were not abstract numbers—they translated into hiring, investment, and consumer spending. Yet they also carried an implicit warning: as economies accelerated, central banks would eventually have to reckon with the question of when to withdraw the monetary support that had kept markets afloat. That reckoning, when it came, would reshape the calculus for investors who had grown accustomed to easy money.
Citações Notáveis
The increasing strength of the UK economy's rebound will cause the central bank to mull over tapering its current stimulus support. Any hawkish signals could well send the FTSE back below 7,000.— Connor Campbell, market analyst at SpreadEX
A Conversa do Hearth Outra perspectiva sobre a história
Why does a 0.1% move in the STOXX 600 matter enough to write about? That's barely movement at all.
It's not the move itself—it's what the move signals. When you're near all-time highs and you're still climbing, even slowly, it means there's no selling pressure. The market is saying: we believe in this.
And the earnings beat rate of 73%—is that actually unusual?
Very. The normal rate is 51%. So companies are beating expectations by a factor of 1.4. That tells you either management was sandbagging their guidance, or the recovery is genuinely outpacing what people thought six months ago.
What about the central bank angle? Why is that a threat?
Because stimulus has been the invisible hand supporting everything. When central banks start talking about tapering, they're saying the crutch is coming away. Markets have to stand on their own legs. If the economy is strong enough to justify that, fine. But if it's not, you get a correction.
So the FTSE could fall below 7,000 if the Bank of England sounds too hawkish?
That's what the analyst is saying. It's a warning: the same strength that's driving stocks higher is also the thing that will eventually force central banks to stop supporting them. It's a paradox.
And the vaccine IP waiver—why did that crater Novavax and Moderna?
Because if patents are waived, anyone can manufacture the vaccine. That destroys the pricing power these companies built. Suddenly they're competing on volume and cost, not exclusivity. The market repriced them instantly.